Gensia Inc., SkyePharma, Boehringer Mannheim Corp. deal

The companies signed a letter of intent to restructure the terms of their agreement to develop an AB rated equivalent formulation

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE